DOCSLIB.ORG

Research Ethics Committee Reference Number

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Research Ethics Committee Reference Number Minimum Maximum Total Number Number Of Number Of Target Date To Research Ethics Integrated Research Date Agreed to Of Patients Date That The Total Number Of Target Number Of Patients Agreed Patients Agreed Recruit Reason For Closure Committee Application System Name of Trial recruit target Recruited At Trial Closed To Study Participants Patients Agreed? (Enter Same In (Enter Same In Patients Of Trial Reference Number Number number of patients The Agreed Recruitment Recruited Both If Only One Both If Only One Agreed? Target Date Number) Number) Not Available / Not Withdrawn By 15/LO/0834 172183 WO29522 (Impassion-130) Date Agreed 31/07/2017 3 05/06/2017 3 Agreed Sponsor Open-Label Study to Compare the Efficacy of Abemaciclib plus Trastuzumab with or without Fulvestrant to Standard-of-Care 16/LO/0595 198560 Chemotherapy of Physician’s Choice plus Trastuzumab in Number Agreed 6 6 Date Agreed 31/12/2018 7 02/02/2018 7 Recruitment Finished Women with HR+, HER2+ Locally Advanced or Metastatic Breast Cancer A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PLACEBO- CONTROLLED PHASE II STUDY OF THE EFFICACY AND SAFETY OF TRASTUZUMAB EMTANSINE IN COMBINATION WITH 16/EM/0320 208246 ATEZOLIZUMAB OR ATEZOLIZUMAB-PLACEBO IN PATIENTS Number Agreed 2 2 Date Agreed 30/06/2017 3 28/07/2017 3 Recruitment Finished WITH HER2-POSITIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER WHO HAVE RECEIVED PRIOR TRASTUZUMAB AND TAXANE BASED THERAPY. An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and postmenopausal women with 16/EE/0463 214371 Range Agreed 8 12 Date Agreed 31/12/2019 10 16/10/2017 10 Recruitment Finished hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (ABC) with no prior hormonal therapy for advanced disease A phase 1, open-label, non-randomized, dose escalating safety, tolerability, harmacokinetic, and pharmacodynamic study of tas- Withdrawn By 14/LO/1081 156436 Number Agreed 50 50 Date Agreed 31/01/2017 18 31/10/2017 25 119, as monotherapy and in combination with docetaxel, in Sponsor patients with advanced solid tumours DOSE-ESCALATING SAFETY TRIAL OF TISSUE FACTOR SPECIFIC ANTIBODY DRUG CONJUGATE (HUMAX®-TF-ADC) IN PATIENTS 15/LO/1284 179637 Number Agreed 26 26 Date Agreed 01/10/2016 3 14/06/2017 6 Recruitment Finished WITH LOCALLY ADVANCED AND/OR METASTATIC SOLID TUMORS KNOWN TO EXPRESS TISSUE FACTOR 16/ES/0004 192492 D081KC00001 (MEDIOLA) Advanced Solid Tumours Number Agreed 5 5 Date Agreed 30/09/2017 5 29/05/2017 5 Recruitment Finished A phase Ib, Open-Label, Dose Escalation and Expansion Study of Demcizumab Plus Pembrolizumab and Demcizumab plus Withdrawn By 16/LO/0397 191752 Number Agreed 10 10 Date Agreed 31/03/2017 5 10/04/2017 5 Pembrolizumab, Pemetrexed and Carboplatin in Patients with Sponsor Locally Advanced or Metastatic Solid Tumors A phase I open-label, dose escalation study to investigate the safety, pharmacokinetics, pharmacodynamics and clinical Withdrawn By 14/LO/0044 139567 Number Agreed 25 25 Date Agreed 01/03/2015 2 19/06/2017 16 activity of GSK2816126 in subjects with relapsed/refractory Sponsor diffuse large B cell and transformed follicular lymphoma An Open-Label Study of the Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Profile of VX-970 as a 14/LO/0372 148591 Number Agreed 40 40 Date Agreed 31/10/2015 31 27/09/2017 71 Recruitment Finished Single Agent and in Combination With Carboplatin in Subjects With Advanced Solid Tumors IMPALA - Evaluation of an immunomodulatory maintenance 14/SC/0295 154130 treatment in patients with metastatic colorectal cancer with Number Agreed 10 10 Date Agreed 01/10/2019 23 11/05/2017 23 Recruitment Finished tumour reduction during induction treatment 15/LO/1246 180129 CARRIE Range Agreed 2 6 Date Agreed 29/10/2015 3 05/05/2017 3 Recruitment Finished GAST-4466 - GS-US-296-1080, A Study to evaluate the 16/LO/0334 193988 Number Agreed 3 3 Date Agreed 31/07/2018 5 12/05/2017 5 Recruitment Finished efficacy&safety of GS-5745 Randomized, Double-Blind, Phase 2 Study of Ramucirumab or Merestinib or Placebo plus Cisplatin and Gemcitabine as First- 16/NW/0379 200426 Number Agreed 6 6 Date Agreed 30/05/2017 1 28/07/2017 2 Recruitment Finished Line Treatment in Patients with Advanced or Mmetastatic Biliary Tract Cancer A Phase 2, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of GS-5745 Combined with Nivolumab 16/EM/0408 211983 versus Nivolumab Alone in Subjects with Unresectable or Range Agreed 1 4 Date Agreed 01/03/2018 14 10/04/2017 14 Recruitment Finished Recurrent Gastric or Gastroesophageal Junction Adenocarcinoma A Randomized, Active-Controlled, Partially Blinded, Biomarker Select, Phase III Clinical Trial of Pembrolizumab as Monotherapy and in Combination with Cisplatin+5-Fluorouracil versus 15/WS/0174 182797 Range Agreed 1 5 Date Agreed 30/04/2019 0 03/05/2017 0 Recruitment Finished Placebo+Cisplatin+5-Fluorouracil as First-Line Treatment in Subjects with Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma A Novel Phase I/IIa Open-label Study of IMM-101 in Withdrawn By 16/LO/1784 211244 Combination with Selected Standard of Care (SOC) Regimens in Range Agreed 1 40 Date Agreed 31/03/2019 0 31/07/2017 0 Sponsor Patients with Metastatic or Unresectable Cancer at Study Entry RANDOMIZED, DOUBLE-BLIND, PHASE 3 STUDY EVALUATING 15/LO/2100 192155 Range Agreed 1 4 Date Agreed 01/12/2017 4 30/11/2017 4 Recruitment Finished TAS-102 PLUS ElevatION:CRC-101: A Phase Ib study of PDR001 in combination Not Available / 17/EM/0272 228700 with bevacizumab and mFOLFOX6 as first line therapy in Number Agreed 3 3 08/11/2017 1 Recruitment Finished Not Agreed patients with metastatic MSS colorectal cancer 16/NE/0027 187317 Javelin Ovarian 200 B9991009 Number Agreed 6 6 Date Agreed 30/06/2017 15 19/04/2017 13 Recruitment Finished A PHASE 3 OPEN-LABEL RANDOMIZED STUDY OF QUIZARTINIB (AC220) MONOTHERAPY VERSUS SALVAGE CHEMOTHERAPY IN SUBJECTS WITH FLT3-ITD POSITIVE ACUTE MYELOID LEUKEMIA 14/EM/0130 149751 Number Agreed 5 5 Date Agreed 29/05/2015 10 01/09/2017 11 Recruitment Finished (AML) REFRACTORY TO OR RELAPSED AFTER FIRST-LINE TREATMENT WITH OR WITHOUT HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) CONSOLIDATION A randomized, multicenter, open label, non-inferiority, phase 3 Not Available / Not Not Available / 15/NW/0492 181246 study of ACP-196 versus Ibrutinib in previously treated subjects 31/10/2017 3 Recruitment Finished Agreed Not Agreed with high risk chronic lymphocytic leukaemia 16/SC/0068 196245 Fusion MDS-001 Range Agreed 1 4 Date Agreed 15/07/2017 4 06/11/2017 7 Recruitment Finished KEYNOTE 048 - A Phase 3 Clinical Trial of Pembrolizumab (MK- 16/LO/1133 203679 3475) in First Line Treatment of Recurrent/Metastatic Head and Range Agreed 6 11 Date Agreed 22/12/2016 11 12/04/2017 12 Recruitment Finished Neck Squamous Cell Carcinoma An Open-Label, Single-Arm, Multicenter, Phase 2 Trial of Withdrawn By 16/LO/1799 199959 Number Agreed 3 3 Date Agreed 25/07/2018 2 10/10/2017 2 Lenvatinib for the Treatment of Anaplastic Thyroid Cancer (ATC) Sponsor 15/EM/0312 141696 Ascend 7: Novartis Brain Mets study - new lung study Number Agreed 2 2 Date Agreed 01/07/2018 2 15/09/2017 2 Recruitment Finished An Open-Label, Randomized Phase 3 Trial of Nivolumab and Nivolumab plus Ipilimumab versus Platinum Doublet Withdrawn By 15/SC/0475 174852 Number Agreed 6 6 Date Agreed 31/08/2019 4 17/08/2017 4 Chemotherapy in Patients with Chemotherapy-Naïve Stage IV or Sponsor Recurrent Non-Small Cell Lung Cancer (NSCLC) CheckMate 451: CHECKpoint pathway and nivolumab clinical 15/EE/0418 188945 Number Agreed 4 4 Date Agreed 14/10/2017 3 11/09/2017 3 Recruitment Finished Trial Evaluation 451 A Phase III, Randomized, Open-Label, Multi-Center, Safety and Efficacy Study to Evaluate Nab-Paclitaxel (Abraxane®) as Withdrawn By 16/LO/1032 199608 Maintenance Treatment after Induction with Nab-Paclitaxel plus Range Agreed 2 10 Date Agreed 31/05/2017 1 02/06/2017 1 Sponsor Carboplatin in Subjects with Squamous Cell Non-Small Cell Lung Cancer (NSCLC) A Phase 2, Multicenter Study of the EZH2 Inhibitor Tazemetostat 16/SC/0341 204761 in Adult Subjects with Relapsed or Refractory Malignant Range Agreed 5 6 Date Agreed 31/05/2018 6 18/05/2017 6 Recruitment Finished Mesothelioma with BAP1 Loss of Function A Phase 3 Multicenter Open-label Study of Brigatinib versus 16/EM/0165 203281 Range Agreed 1 3 Date Agreed 31/07/2017 1 28/07/2017 1 Recruitment Finished Crizotinib A Randomized, Placebo Controlled Phase 2b/3 Study of ABT-414 with Concurrent Chemoradiation and Adjuvant Temozolomide 15/LO/1950 184545 in Subjects with Newly Diagnosed Glioblastoma (GBM) with Range Agreed 4 10 Date Agreed 30/03/2018 4 15/12/2017 4 Recruitment Finished Epidermal Growth Factor Receptor (EGFR) Amplification (Intellance 1) A Phase 1/2 multicenter, open-label, dose-finding study to assess the safety, tolerability and preliminary efficacy of weekly 13/LO/1272 133720 Number Agreed 5 5 Date Agreed 30/07/2016 9 18/10/2017 9 Recruitment Finished paclitaxel in paediatric patients with recurrent or refractory solid tumours PROSPER: A Multinational, Phase 3, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Enzalutamide in Not Available / 13/LO/1081 132715 Number Agreed 25 25 14/04/2017 8 Recruitment Finished Patients With Nonmetastatic Castration-Resistant Prostate Not Agreed Cancer CheckMate 401: CHECKpoint pathway and nivoluMAb clinical 15/EE/0448 189797 Range Agreed 1 5 Date
Load more

Recommended publications
  • Clinical Protocol
    OncoMed Pharmaceuticals, Inc. Demcizumab CLINICAL PROTOCOL Protocol No. M18-006 Title: YOSEMITE: A 3-Arm Phase 2 Double-Blind Randomized StudY of Gemcitabine, Abraxane® Plus PlacebO versuS GEMcitabIne, Abraxane® plus 1 or 2 TruncatEd Courses of Demcizumab in Subjects with 1st-Line Metastatic Pancreatic Ductal Adenocarcinoma Version: 23 October 2014 Amendment 1: 24 November 2014 Amendment 2: 10 February 2015 Amendment 3: 28 May 2015 Amendment 4: 31 March 2016 Amendment 5: 19 December 2016 EudraCT Number: 2014‐003355‐56 Sponsor: OncoMed Pharmaceuticals, Inc. 800 Chesapeake Drive Redwood City, CA 94063 Phone: 650-995-8200 CONFIDENTIAL This document contains proprietary and confidential information of OncoMed Pharmaceuticals, Inc. Acceptance of this document constitutes agreement by the recipient that no previously unpublished information contained herein will be published or disclosed without the prior written approval of OncoMed Pharmaceuticals, Inc. with the exception that this document may be disclosed to study personnel under your supervision who need to know the contents for conducting the study and appropriate Institutional Review Boards/Ethics Committees under the condition that the personnel have agreed to keep this information confidential. The foregoing shall not apply to disclosure required by governmental regulations or laws; however, OncoMed Pharmaceuticals, Inc. shall be promptly notified of any such disclosure. Protocol M18-006, Amendment 5 Page 1 of 130 CONFIDENTIAL 19 December 2016 OncoMed Pharmaceuticals, Inc. Demcizumab SPONSOR CONTACTS Medical Monitor: ___________________ (Primary) ___________________________ Email: ___________________ Phone: ____________________ Medical Monitor: ___________________ (Secondary) ___________________ Email: ___________________ Phone: ___________________ Safety Reporting: Europe, Australia Phone: ___________________ Fax: ___________________ United States Phone: ___________________ Fax: ___________________ Protocol M18-006, Amendment 5 Page 2 of 130 CONFIDENTIAL 19 December 2016 OncoMed Pharmaceuticals, Inc.
    [Show full text]
  • Precision Medicine for Human Cancers with Notch Signaling Dysregulation (Review)
    INTERNATIONAL JOURNAL OF MOleCular meDICine 45: 279-297, 2020 Precision medicine for human cancers with Notch signaling dysregulation (Review) MASUKO KATOH1 and MASARU KATOH2 1M & M PrecMed, Tokyo 113-0033; 2Department of Omics Network, National Cancer Center, Tokyo 104-0045, Japan Received September 16, 2019; Accepted November 20, 2019 DOI: 10.3892/ijmm.2019.4418 Abstract. NOTCH1, NOTCH2, NOTCH3 and NOTCH4 are conjugate (ADC) Rova-T, and DLL3-targeting chimeric antigen transmembrane receptors that transduce juxtacrine signals of receptor‑modified T cells (CAR‑Ts), AMG 119, are promising the delta-like canonical Notch ligand (DLL)1, DLL3, DLL4, anti-cancer therapeutics, as are other ADCs or CAR-Ts targeting jagged canonical Notch ligand (JAG)1 and JAG2. Canonical tumor necrosis factor receptor superfamily member 17, Notch signaling activates the transcription of BMI1 proto-onco- CD19, CD22, CD30, CD79B, CD205, Claudin 18.2, fibro- gene polycomb ring finger, cyclin D1, CD44, cyclin dependent blast growth factor receptor (FGFR)2, FGFR3, receptor-type kinase inhibitor 1A, hes family bHLH transcription factor 1, tyrosine-protein kinase FLT3, HER2, hepatocyte growth factor hes related family bHLH transcription factor with YRPW receptor, NECTIN4, inactive tyrosine-protein kinase 7, inac- motif 1, MYC, NOTCH3, RE1 silencing transcription factor and tive tyrosine-protein kinase transmembrane receptor ROR1 transcription factor 7 in a cellular context-dependent manner, and tumor-associated calcium signal transducer 2. ADCs and while non-canonical Notch signaling activates NF-κB and Rac CAR-Ts could alter the therapeutic framework for refractory family small GTPase 1. Notch signaling is aberrantly activated cancers, especially diffuse-type gastric cancer, ovarian cancer in breast cancer, non-small-cell lung cancer and hematological and pancreatic cancer with peritoneal dissemination.
    [Show full text]
  • The Role of Cancer Stem Cells in Colorectal Cancer: from the Basics to Novel Clinical Trials
    cancers Review The Role of Cancer Stem Cells in Colorectal Cancer: From the Basics to Novel Clinical Trials Céline Hervieu 1 , Niki Christou 1,2 , Serge Battu 1 and Muriel Mathonnet 1,2,* 1 EA 3842 CAPTuR “Control of Cell Activation in Tumor Progression and Therapeutic Resistance”, Faculty of Medicine, Genomics, Environment, Immunity, Health and Therapeutics (GEIST) Institute, University of Limoges, 87025 Limoges CEDEX, France; [email protected] (C.H.); [email protected] (N.C.); [email protected] (S.B.) 2 Department of General, Endocrine and Digestive Surgery, University Hospital of Limoges, 87025 Limoges CEDEX, France * Correspondence: [email protected] Simple Summary: Cancer stem cells (CSCs) fuel tumor growth, metastasis and resistance to therapy in colorectal cancer (CRC). These cells therefore represent a promising target for the treatment of CRC but are difficult to study because of the complexity of their isolation. This review presents the methods currently used to isolate colorectal CSCs as well as the techniques for characterizing these cells with their advantages and limitations. The aim of this review is to provide a state-of-the-art on the clinical relevance of CSCs in CRC by outlining current treatments for CRC, the resistance mechanisms developed by CSCs to overcome them, and ongoing clinical trials of drugs targeting CSCs in CRC. Overall, this review addresses the complexity of studying CSCs in CRC research and developing clinically effective treatments to enable CRC patients to achieve a short and long-term therapeutic response. Citation: Hervieu, C.; Christou, N.; Battu, S.; Mathonnet, M. The Role of Abstract: The treatment options available for colorectal cancer (CRC) have increased over the years Cancer Stem Cells in Colorectal and have significantly improved the overall survival of CRC patients.
    [Show full text]
  • Predictive QSAR Tools to Aid in Early Process Development of Monoclonal Antibodies
    Predictive QSAR tools to aid in early process development of monoclonal antibodies John Micael Andreas Karlberg Published work submitted to Newcastle University for the degree of Doctor of Philosophy in the School of Engineering November 2019 Abstract Monoclonal antibodies (mAbs) have become one of the fastest growing markets for diagnostic and therapeutic treatments over the last 30 years with a global sales revenue around $89 billion reported in 2017. A popular framework widely used in pharmaceutical industries for designing manufacturing processes for mAbs is Quality by Design (QbD) due to providing a structured and systematic approach in investigation and screening process parameters that might influence the product quality. However, due to the large number of product quality attributes (CQAs) and process parameters that exist in an mAb process platform, extensive investigation is needed to characterise their impact on the product quality which makes the process development costly and time consuming. There is thus an urgent need for methods and tools that can be used for early risk-based selection of critical product properties and process factors to reduce the number of potential factors that have to be investigated, thereby aiding in speeding up the process development and reduce costs. In this study, a framework for predictive model development based on Quantitative Structure- Activity Relationship (QSAR) modelling was developed to link structural features and properties of mAbs to Hydrophobic Interaction Chromatography (HIC) retention times and expressed mAb yield from HEK cells. Model development was based on a structured approach for incremental model refinement and evaluation that aided in increasing model performance until becoming acceptable in accordance to the OECD guidelines for QSAR models.
    [Show full text]
  • Classification Decisions Taken by the Harmonized System Committee from the 47Th to 60Th Sessions (2011
    CLASSIFICATION DECISIONS TAKEN BY THE HARMONIZED SYSTEM COMMITTEE FROM THE 47TH TO 60TH SESSIONS (2011 - 2018) WORLD CUSTOMS ORGANIZATION Rue du Marché 30 B-1210 Brussels Belgium November 2011 Copyright © 2011 World Customs Organization. All rights reserved. Requests and inquiries concerning translation, reproduction and adaptation rights should be addressed to [email protected]. D/2011/0448/25 The following list contains the classification decisions (other than those subject to a reservation) taken by the Harmonized System Committee ( 47th Session – March 2011) on specific products, together with their related Harmonized System code numbers and, in certain cases, the classification rationale. Advice Parties seeking to import or export merchandise covered by a decision are advised to verify the implementation of the decision by the importing or exporting country, as the case may be. HS codes Classification No Product description Classification considered rationale 1. Preparation, in the form of a powder, consisting of 92 % sugar, 6 % 2106.90 GRIs 1 and 6 black currant powder, anticaking agent, citric acid and black currant flavouring, put up for retail sale in 32-gram sachets, intended to be consumed as a beverage after mixing with hot water. 2. Vanutide cridificar (INN List 100). 3002.20 3. Certain INN products. Chapters 28, 29 (See “INN List 101” at the end of this publication.) and 30 4. Certain INN products. Chapters 13, 29 (See “INN List 102” at the end of this publication.) and 30 5. Certain INN products. Chapters 28, 29, (See “INN List 103” at the end of this publication.) 30, 35 and 39 6. Re-classification of INN products.
    [Show full text]
  • Primary and Acquired Resistance to Immunotherapy in Lung Cancer: Unveiling the Mechanisms Underlying of Immune Checkpoint Blockade Therapy
    cancers Review Primary and Acquired Resistance to Immunotherapy in Lung Cancer: Unveiling the Mechanisms Underlying of Immune Checkpoint Blockade Therapy Laura Boyero 1 , Amparo Sánchez-Gastaldo 2, Miriam Alonso 2, 1 1,2,3, , 1,2, , José Francisco Noguera-Uclés , Sonia Molina-Pinelo * y and Reyes Bernabé-Caro * y 1 Institute of Biomedicine of Seville (IBiS) (HUVR, CSIC, Universidad de Sevilla), 41013 Seville, Spain; [email protected] (L.B.); [email protected] (J.F.N.-U.) 2 Medical Oncology Department, Hospital Universitario Virgen del Rocio, 41013 Seville, Spain; [email protected] (A.S.-G.); [email protected] (M.A.) 3 Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), 28029 Madrid, Spain * Correspondence: [email protected] (S.M.-P.); [email protected] (R.B.-C.) These authors contributed equally to this work. y Received: 16 November 2020; Accepted: 9 December 2020; Published: 11 December 2020 Simple Summary: Immuno-oncology has redefined the treatment of lung cancer, with the ultimate goal being the reactivation of the anti-tumor immune response. This has led to the development of several therapeutic strategies focused in this direction. However, a high percentage of lung cancer patients do not respond to these therapies or their responses are transient. Here, we summarized the impact of immunotherapy on lung cancer patients in the latest clinical trials conducted on this disease. As well as the mechanisms of primary and acquired resistance to immunotherapy in this disease. Abstract: After several decades without maintained responses or long-term survival of patients with lung cancer, novel therapies have emerged as a hopeful milestone in this research field.
    [Show full text]
  • PD-1 / PD-L1 Combination Therapies
    PD-1 / PD-L1 Combination Therapies Jacob Plieth & Edwin Elmhirst – May 2017 Foreword Sprinkling the immuno-oncology dust When in November 2015 EP Vantage published its first immuno- oncology analysis we identified 215 studies of anti-PD-1/PD-L1 projects combined with other approaches, and called this an important industry theme. It is a measure of how central combos have become that today, barely 18 months on, that total has been blown out of the water. No fewer than 765 studies involving combinations of PD-1 or PD-L1 assets are now listed on the Clinicaltrials.gov registry. This dazzling array owes much to the transformational nature of the data seen with the first wave of anti-PD-1/PD-L1 MAbs. It also indicates how central combinations will be in extending immuno-oncology beyond just a handful of cancers, and beyond certain patient subgroups. But the combo effort is as much about extending the reach of currently available drugs like Keytruda, Opdivo and Tecentriq as it is about making novel approaches viable by combining them with PD-1/PD-L1. On a standalone basis several of the industry’s novel oncology projects have underwhelmed. As data are generated it will therefore be vital for investors to tease out the effect of combinations beyond that of monotherapy, and it is doubtful whether the sprinkling of magic immuno-oncology dust will come to the rescue of substandard products. This is not stopping many companies, as the hundreds of combination studies identified here show. This report aims to quantify how many trials are ongoing with which assets and in which cancer indications, as well as suggesting reasons why some of the most popular approaches are being pursued.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2017/0172932 A1 Peyman (43) Pub
    US 20170172932A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2017/0172932 A1 Peyman (43) Pub. Date: Jun. 22, 2017 (54) EARLY CANCER DETECTION AND A 6LX 39/395 (2006.01) ENHANCED IMMUNOTHERAPY A61R 4I/00 (2006.01) (52) U.S. Cl. (71) Applicant: Gholam A. Peyman, Sun City, AZ CPC .......... A61K 9/50 (2013.01); A61K 39/39558 (US) (2013.01); A61K 4I/0052 (2013.01); A61 K 48/00 (2013.01); A61K 35/17 (2013.01); A61 K (72) Inventor: sham A. Peyman, Sun City, AZ 35/15 (2013.01); A61K 2035/124 (2013.01) (21) Appl. No.: 15/143,981 (57) ABSTRACT (22) Filed: May 2, 2016 A method of therapy for a tumor or other pathology by administering a combination of thermotherapy and immu Related U.S. Application Data notherapy optionally combined with gene delivery. The combination therapy beneficially treats the tumor and pre (63) Continuation-in-part of application No. 14/976,321, vents tumor recurrence, either locally or at a different site, by filed on Dec. 21, 2015. boosting the patient’s immune response both at the time or original therapy and/or for later therapy. With respect to Publication Classification gene delivery, the inventive method may be used in cancer (51) Int. Cl. therapy, but is not limited to such use; it will be appreciated A 6LX 9/50 (2006.01) that the inventive method may be used for gene delivery in A6 IK 35/5 (2006.01) general. The controlled and precise application of thermal A6 IK 4.8/00 (2006.01) energy enhances gene transfer to any cell, whether the cell A 6LX 35/7 (2006.01) is a neoplastic cell, a pre-neoplastic cell, or a normal cell.
    [Show full text]
  • Understanding and Targeting Resistance to Anti-Angiogenic Therapies
    Review Article Understanding and targeting resistance to anti-angiogenic therapies Jeffrey M. Clarke, Herbert I. Hurwitz Duke Cancer Institute, Duke University Medical Center, Durham, NC, USA Corresponding to: Jeffrey M. Clarke. Duke Cancer Institute, Duke University Medical Center, Durham, NC, USA. Email: [email protected]. Abstract: Therapies targeting tumor angiogenesis are used in a variety of malignancies, however not all patients benefit from treatment and impact on tumor control may be transient and modest. Mechanisms of resistance to anti-angiogenic therapies can be broadly categorized into VEGF-axis dependent alterations, non-VEGF pathways, and stromal cell interactions. Complimentary combinations of agents that inhibit alternative mechanisms of blood vessel formation may optimize inhibition of angiogenesis and improve clinical benefit for patients. The purpose of this review is to detail the preclinical evidence for mechanisms of angiogenic resistance and provide an overview of novel therapeutic approaches exploiting these pathways. Key Words: Cancer; angiogenesis; resistance; VEGF; vascular endothelial growth factor; colorectal cancer Submitted May 02, 2013. Accepted for publication May 21, 2013. doi: 10.3978/j.issn.2078-6891.2013.036 Scan to your mobile device or view this article at: http://www.thejgo.org/article/view/1282/html Introduction (RTK) and downstream targets, and steric blockade of the VEGFRs (using a monoclonal antibody). FDA approved Therapies targeting angiogenesis are an integral modality of agents with anti-VEGF properties include bevacizumab, modern anti-tumor treatment for a number of malignancies, ziv-aflibercept, and multiple small molecule RTK inhibitors in particular metastatic colorectal cancer (CRC). Broadly, (i.e., sorafenib, sunitinib, pazopanib, axitinib, cabozantinib, tumor angiogenesis relies on a highly complex program of and regorafenib).
    [Show full text]
  • WO 2016/176089 Al 3 November 2016 (03.11.2016) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2016/176089 Al 3 November 2016 (03.11.2016) P O P C T (51) International Patent Classification: BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, A01N 43/00 (2006.01) A61K 31/33 (2006.01) DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, (21) International Application Number: KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, PCT/US2016/028383 MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, (22) International Filing Date: PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, 20 April 2016 (20.04.2016) SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (25) Filing Language: English (84) Designated States (unless otherwise indicated, for every (26) Publication Language: English kind of regional protection available): ARIPO (BW, GH, (30) Priority Data: GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, 62/154,426 29 April 2015 (29.04.2015) US TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, (71) Applicant: KARDIATONOS, INC. [US/US]; 4909 DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, Lapeer Road, Metamora, Michigan 48455 (US).
    [Show full text]
  • Double Trouble Sinks Oncomed As Investors Look to Earlier Assets
    April 10, 2017 Double trouble sinks Oncomed as investors look to earlier assets Jonathan Gardner Oncomed looks like it has fewer strategic options after the twin setbacks of a phase II pancreatic cancer failure for demcizumab and its partner Bayer’s decision to opt out of a licensing deal for two other projects. Shares fell 36% to $5.65 yesterday in spite of the group’s efforts to put the two disappointments in a positive light – Celgene-partnered partnered demcizumab might be a viable candidate in first-line lung cancer, while Bayer’s decision means Oncomed still has full ownership of two phase II-ready cancer agents, executives said. Nevertheless, they said a portfolio review was underway, highlighting early-stage biomarker-driven projects with potential benefit in immuno-oncology. Testing times Two near-term catalysts should determine whether Oncomed matures into a late-stage developer or if it must turn back to a focus on phase I assets: readouts of the Denali phase II clinical trial of demcizumab in NSCLC and the Pinnacle phase I/II trial of tarextumab in small-cell lung cancer. Denali tests demcizumab, an anti-DLL4 antibody, in first-line non-squamous NSCLC in combination with carboplatin and pemetrexed against the two chemotherapy agents. It was initiated in late 2014, before the anti-PD-1 drug Keytruda reshaped first-line NCSLC treatment, and thus it will likely take additional mid-stage trials before a clear idea emerges of where it might fit into treatment protocols. Oncomed executives are aware of this, saying on a conference call with investors yesterday that when Denali results are released they will also unblind data from a phase I trial of demcizumab in combination with Keytruda in solid tumours.
    [Show full text]
  • Phase 1B Study of Demcizumab Plus Pemetrexed and Carboplatin In
    Phase 1b Study of Demcizumab plus Pemetrexed and Carboplatin in Patients with 1st line Non-Small Cell Lung Cancer (NSCLC) 1 McKeage M, 2 Kotasek D, 3 Markman B, 4 Millward M, 5 Hidalgo M, 6 Jameson M, 7 D Harris, 8 Stagg R, 8 Dupont J, 9 Hughes B 1University of Auckland, Auckland, New Zealand; 2 Adelaide Cancer Centre, Adelaide, Australia; 3 Monash Medical Centre, Monash University, Melbourne, Australia; 4 Sir Charles Gairdner Hospital, Perth, Australia; 5 CNIO-CIOCC-START, Madrid, Spain; 6 Waikato Hospital, Hamilton, New Zealand; 7 Christchurch Hospital, Christchurch, New Zealand; 8 OncoMed Pharmaceutical, Redwood City, CA; and 9 The Royal Brisbane and Woman Hospital, Brisbane, Australia. Background AEs (All Grades) in >20% of Patients Pharmacokinetics %ChangeinRECISTTargetLesionSize% Change in RECIST Target Lesion Size Three Patients at DEM 5 mg/kg Q3W by Dose Level (mg/kg) Progression Free > 480 Days There is accumulating evidence that the cell types within tumors are heterogeneous •To assess the impact of pemetrexedand carboplatinon demcizumabPK, plasma 100 and that a subset of the cells retain the property to self-renew and give rise to more Dose Level – mg/kg 5 2.5 5 5 7.5 Total (%) samples were collected pre- and post-infusion on Study Days 21 and 63, and Pt 1: Stage IV NSCLC (adenocarcinoma) differentiated progeny. These cells, called cancer stem cells (CSCs) or tumor Expansion analyzed for demcizumab concentration. 80 initiating cells drive tumor growth and metastasis and are more resistant to N6686430 •Disease in left lung, mediastinum, pleural & pericardial effusions, bone •Treated with DEM at 5mg/kg Q3W & carboplatin+ pemetrexed chemotherapy and radiotherapy than the remaining tumor cells.
    [Show full text]